Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia.
about
Very early discharge versus early discharge versus non-early discharge in children with cancer and febrile neutropeniaIntravenous immunoglobulins for the treatment of infections in patients with haematological cancersAntibiotics for the prevention of infections in cancer patients receiving myelosuppressive chemotherapy or haematopoetic stem cell transplantationOral versus intravenous antibiotic treatment for febrile neutropenia in cancer patientsPrimary prophylactic colony-stimulating factors for the prevention of chemotherapy-induced febrile neutropenia in breast cancer patientsAntibiotics plus colony stimulating factors versus antibiotics alone for the prevention of infections in cancer patients receiving myelosuppressive chemotherapy or haematopoetic stem cell transplantationEmpirical antibiotic therapy for febrile neutropenia in pediatric cancer patientsBeta-lactam versus beta-lactam-aminoglycoside combination therapy in cancer patients with neutropeniaAntibiotic prophylaxis for bacterial infections in afebrile neutropenic patients following chemotherapyQ24235340Antibiotics plus colony stimulating factors versus antibiotics alone for the prevention of infections in cancer patients receiving myelosuppressive chemotherapy or haematopoetic stem cell transplantationOutpatient treatment for patients with cancer who develop a low-risk febrile neutropenic eventIntravenous immunoglobulins for the treatment of infections in patients with haematological cancersAnti-pseudomonal beta-lactams for the initial, empirical, treatment of febrile neutropenia: comparison of beta-lactamsVery early discharge versus early discharge versus non-early discharge in pediatric cancer patients with febrile neutropeniaGranulopoiesis-stimulating factors to prevent adverse effects in the treatment of malignant lymphomaColony-stimulating factors for the prevention of chemotherapy induced febrile neutropenia in breast cancer patientsAntibiotics plus colony stimulating factors versus antibiotics alone for the prevention of infections in cancer patients receiving myelosuppressive chemotherapy or haematopoetic stem cell transplantationProphylactic antibiotics or G-CSF for the prevention of infections and improvement of survival in cancer patients undergoing chemotherapyAntibiotics plus colony stimulating factors versus CSFs alone and antibiotics plus CSFs versus no prophylaxis for the prevention of infections in cancer patients receiving myelosuppressive chemotherapy or haematopoetic stem cell transplantationAnti-pseudomonal beta-lactam monotherapy for the initial, empirical, treatment of febrile neutropenia: comparison of beta-lactamsProphylactic antibiotics and G-CSF for the prevention of infections and improvement of survival in cancer patients undergoing chemotherapySingle-agent antibiotic therapy for the initial, empirical, treatment of febrile neutropenia: comparison of beta-lactamsAntibiotic prophylaxis for bacterial infections in afebrile neutropenic patients following chemotherapyOral versus intravenous antibiotic treatment for febrile neutropenia in cancer patientsBeta-lactam versus beta-lactam-aminoglycoside combination therapy in cancer patients with neutropeniaAntibiotic prophylaxis for bacterial infections in afebrile neutropenic patients following chemotherapyOral versus intravenous antibiotic treatment for febrile neutropenia in cancer patientsKeratinocyte production of cathelicidin provides direct activity against bacterial skin pathogensDeletion of the two-component histidine kinase gene (CHK1) of Candida albicans contributes to enhanced growth inhibition and killing by human neutrophils in vitro.Cancer cachexia--pathophysiology and managementPhase II, randomized, open-label study of pegfilgrastim-supported VDC/IE chemotherapy in pediatric sarcoma patientsThe benefit of the neutropenic diet: fact or fiction?A low dose of recombinant interleukin 1 protects granulocytopenic mice from lethal gram-negative infectionG-CSF and GM-CSF in NeutropeniaPneumonia in the neutropenic cancer patientCovering all the Bases: Preclinical Development of an Effective Staphylococcus aureus VaccineNeutrophils in innate host defense against Staphylococcus aureus infectionsA comparison of efficacy of sargramostim (yeast-derived RhuGM-CSF) and filgrastim (bacteria-derived RhuG-CSF) in the therapeutic setting of chemotherapy-induced myelosuppressionEffect of vincristine sulfate on Pseudomonas infections in monkeys
P2860
Q24186114-3D78AC21-28AC-4C0D-A7F1-07D1D7B3E76EQ24186274-DD0E3DEA-5326-44D1-A7CF-AFE5EB2478A9Q24186282-29FEBC7C-06F7-4F21-A420-E57AFB9BEF0FQ24197538-E7BE6498-91FF-4D8C-B3D6-540F6CC1C40BQ24198118-169FD87D-B2BC-4000-B616-891CFB69EF20Q24200225-4FC81580-53F5-4B70-AED1-75C207A45559Q24201480-D6566FE4-C830-4FCA-BE96-8299B195C068Q24201767-E73C3B9D-B148-4763-A655-51FB29EE4978Q24203869-7D6DCBFD-36FE-4EFA-B6B0-C43EFBE9AF38Q24235340-FCEDB54E-F276-445A-B407-0A2E0F62D44AQ24235345-D7C52CD6-EBC8-4D22-A334-EC773E046301Q24236088-A1C30732-DD73-46E0-A500-F3FD345110BFQ24236448-5C97FDDC-A9BA-4940-BAB8-3CEE184CC5E6Q24236653-C0C8675C-7C81-4CD6-AB69-5341672DFCE6Q24240207-FE419CE8-4957-4267-872D-5966D6904D0BQ24240753-613A44FC-117F-450B-A699-0579757FD3D9Q24240768-9B4985A9-AFD7-4F4A-B367-3A4E521AD25AQ24241475-235A7B7B-0EAC-46CC-ADB5-D862A8C8FE54Q24241680-0FF8AD26-5F72-4003-B566-79DCD78DA59BQ24241689-D04D5538-7FBA-497D-AC09-9606533B045FQ24243072-67DC48C4-63E0-4928-BA59-26695FAA9B22Q24243543-994EDFF4-C9CB-40F0-B557-B58ADBB7FAF8Q24244737-44574710-F376-4985-AA9B-9F6A56D50101Q24245774-4EFFDBAF-90B8-46C8-BC42-3F1F76534331Q24246096-78106C60-62EC-47F9-8346-50769FFBEE1EQ24248048-DE70F381-ACBF-4506-BC10-7C00E3B7565FQ24248143-C3FC8CB6-ACA0-490E-B2B6-017179BA9C1DQ24250480-492EAB13-BD44-442F-B9E7-FB0F2330039BQ24336171-566860BB-5035-4B62-8B6D-BE9F11CD8CA6Q24537152-F0ADD05A-132C-47C8-9BD4-E12CCE17432AQ24605567-FCC332EE-CCFE-48FF-9328-6DD91AFA5009Q24632145-92C85686-AC1B-4B4B-B8B1-8D67E81EBEF1Q24633267-F7C1F451-165D-4FFE-ACE5-05B13FE75E21Q24654068-A65E0BDC-70BC-4CD9-8F27-3E5035041993Q26800954-4444D51C-3159-4F67-A6FC-D399B56D45D9Q26827758-D06D0EC8-E61B-475E-B18E-7F150FC67C3CQ27008338-5BD48BB5-EAE8-4BCD-9FD7-E88394E946C1Q27024628-1A1C9D92-EB94-4AB4-8D75-A2D7F77AE675Q28277632-4DD82BDB-0B9E-43A5-B66C-284CA7082118Q28363646-2BF26EFA-0B53-4705-9474-1B1BE5044180
P2860
Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia.
description
1966 nî lūn-bûn
@nan
1966年の論文
@ja
1966年学术文章
@wuu
1966年学术文章
@zh-cn
1966年学术文章
@zh-hans
1966年学术文章
@zh-my
1966年学术文章
@zh-sg
1966年學術文章
@yue
1966年學術文章
@zh
1966年學術文章
@zh-hant
name
Quantitative relationships bet ...... patients with acute leukemia.
@en
Quantitative relationships bet ...... patients with acute leukemia.
@nl
type
label
Quantitative relationships bet ...... patients with acute leukemia.
@en
Quantitative relationships bet ...... patients with acute leukemia.
@nl
prefLabel
Quantitative relationships bet ...... patients with acute leukemia.
@en
Quantitative relationships bet ...... patients with acute leukemia.
@nl
P2093
P1476
Quantitative relationships bet ...... patients with acute leukemia.
@en
P2093
P304
P356
10.7326/0003-4819-64-2-328
P407
P577
1966-02-01T00:00:00Z